MetaStat

MetaStat Operating Expenses

The Total Operating Expenses of MetaStat (MTST) as of Oct 6, 2026 is 3.57 M USD. In the previous year, Total Operating Expenses was 3.35 M USD — a change of 6.74% (higher).

Operating Expenses

3.57 MUSD

YoY

6.74%

Last updated:

Total Operating Expenses of MetaStat is 2026 3.57 M USD. Total Operating Expenses of MetaStat was 2025 3.35 M USD. It decreases by 6.74% higher compared to the previous year.

The MetaStat Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2014
4.35 M USD
Jan 1, 2015
4.79 M USD
Jan 1, 2016
4.78 M USD
Jan 1, 2017
3.35 M USD
Jan 1, 2018
3.57 M USD
The MetaStat Operating Expenses history
YEAROperating ExpensesYoY
3.57 MUSD+6.74%
3.35 MUSD-29.94%
4.78 MUSD-0.25%
4.79 MUSD+10.11%
4.35 MUSD—
Access this data via the Eulerpool API

MetaStat Stock analysis

What does MetaStat do? MetaStat Inc. is a biopharmaceutical company focused on the development of therapeutics for cancer. It was founded in Massachusetts in 2000 and has been listed on NASDAQ since 2013. The company's main focus is on blocking the protein Meta-1, which is associated with the formation of metastases, in order to stop the spread of cancer. MetaStat's business model is based on marketing medications and diagnostics. They work closely with researchers and clinicians to develop new products and conduct clinical trials. The company operates in two divisions: therapeutics and diagnostics. The therapeutics division focuses on developing medications targeting the Meta-1 protein, while the diagnostics division develops tests to detect Meta-1 protein in patients' blood to identify metastases early on. MetaStat's main product is the MetaSite Breast Test, a diagnostic test for breast cancer that uses proprietary technologies to detect the presence of Meta-1 in tumor tissue. The company also has several therapeutics in the pipeline, with MSC-1, a small molecule that blocks the function of Meta-1 and inhibits the formation of metastases, being the leading product. MetaStat has established partnerships with several research institutions and companies to advance its research and development. In summary, MetaStat is a biopharmaceutical company specializing in the development of therapeutics and diagnostics for cancer. They have developed innovative technology to detect the presence of Meta-1 in tumor tissue and inhibit the formation of metastases. Their main product is the MetaSite Breast Test, which determines the risk of metastases in breast cancer patients. The company has established partnerships with research institutions and companies to advance its research and development and further develop its pipeline of therapeutics. MetaStat is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MetaStat stock

Total Operating Expenses of MetaStat is 3.57 M USD in 2026.

Total Operating Expenses of MetaStat changed from 3.35 M USD to 3.57 M USD, representing a 6.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses MetaStat since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's MetaStat historically and in real time.

Access this data via the Eulerpool API

Income Statement — MetaStat

All Key Metrics — MetaStat